| A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. | lymphoma, |
| The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model. | lymphoma, |
| Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma. | lymphoma, |
| Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. | lymphoma, |
| Targeting the oncogenic tyrosine kinase NPM-ALK in lymphoma: the role of murine models in defining pathogenesis and treatment options. | lymphoma, |
| Oncogenic NPM1-ALK contains the ALK catalytic domain plus NPM1 oligomerization motif and mediates malignant cell transformation by epigenetic silencing of signal transducer and activator of transcription STAT5A in T-cell anaplastic large cell lymphomas. | lymphoma, |
| Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. | lymphoma, |
| Translocations or deregulated expression of ALK contribute to oncogenesis and genetic or pharmacological tools, aimed at neutralizing its activity in anaplastic lymphoma [REVIEW] | lymphoma, |
| ALK protein contributes to NB(neuroblastoma) oncogenesis providing a highly interesting putative therapeutic target in a subset of unfavourable NB tumours. | neuroblastoma, |
| The expression of the dual specificity phosphatase CDC25A, is deregulated in Ba/F3 cells expressing the oncogenic protein NPM/ALK and in human cell lines derived from NPM/ALK-positive anaplastic large cell lymphomas. | lymphoma, |
| Upregulation of the CDC25A phosphatase down-stream of the NPM/ALK oncogene participates to anaplastic large cell lymphoma enhanced proliferation. | lymphoma, |
| IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. | lymphoma, |
| [Oncogenic mutations of ALK are associated with tumorigenesis of neuroblastoma]. | neuroblastoma, |
| NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. | lymphoma, |
| Oncogenic mutations of ALK in neuroblastoma. | neuroblastoma, |
| Data show that anaplastic lymphoma kinase (ALK)-comtaining granules are novel mRNA-containing cytoplasmic foci that could protect translatable mRNAs from degradation, contributing to ALK-mediated oncogenicity. | lymphoma, |
| Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. | lung, |
| The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. | lymphoma, |
| Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. | lung, |
| Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. | lung, |